Compare POR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POR | FOLD |
|---|---|---|
| Founded | 1889 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | N/A | 2007 |
| Metric | POR | FOLD |
|---|---|---|
| Price | $48.87 | $14.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $46.64 | $27.56 |
| AVG Volume (30 Days) | 1.1M | ★ 20.1M |
| Earning Date | 02-13-2026 | 02-18-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $3,511,000,000.00 | $598,704,000.00 |
| Revenue This Year | $4.94 | $21.49 |
| Revenue Next Year | $4.82 | $18.42 |
| P/E Ratio | $17.51 | ★ N/A |
| Revenue Growth | 5.09 | ★ 21.28 |
| 52 Week Low | $39.55 | $5.51 |
| 52 Week High | $51.14 | $14.36 |
| Indicator | POR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 89.90 |
| Support Level | $47.37 | $14.21 |
| Resistance Level | $48.83 | $14.35 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 75.92 | 97.72 |
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.